Biocon and Mylan N.V. will present 48 week results from the HERITAGE study at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1-5. The HERITAGE study compared Ogivri, the first biosimilar for Herceptin approved in the US, to the reference product in patients with metastatic breast cancer in combination with taxanes for the first 24 weeks and then as a monotherapy until progression. Data obtained after 48 weeks of treatment will be included as part of the Clinical Science Symposium titled, ‘The Arrival of Biosimilars,’ on June 4.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
